Galapagos NV (GLPG)

37.20 -0.32 (-0.85%) At close: 04:00PM EST

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,338

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paulus A. Stoffels M.D., Ph.D.	CEO, Chairman, Interim Head of R&D	986.21k	N/A	1962
Mr. Michele Manto M.B.A.	Chief Commercial Officer	636.73k	N/A	1973
Mr. Thad Huston	CFO & COO	N/A	N/A	1970
Ms. Sofie Van Gijsel	Head of Investor Relations	N/A	N/A	N/A
Ms. Valeria Cnossen	General Counsel	N/A	N/A	N/A
Marieke Vermeersch	Head of Corporate Communication	N/A	N/A	N/A
Ms. Annelies Missotten	Chief Human Resources Officer	N/A	N/A	N/A
Ms. Ellen Van Der Aar	Head of Development	N/A	N/A	N/A
Mr. Philippe Alen	Senior VP & Head of Business Development	N/A	N/A	N/A
Mr. Dirk De Naeyer	Head of Development Operations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Corporate governance

Galapagos NV’s ISS governance QualityScore as of 28 November 2023 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.